PLC and PI3K pathways are important in the inhibition of EGF-induced cell migration by gefitinib ('Iressa', ZD1839)

Tadahiko Shien, Hiroyoshi Doihara, Humikata Hara, Hirotoshi Takahashi, Seiji Yoshitomi, Naruto Taira, Youiti Ishibe, Jyun Teramoto, Motoi Aoe, Nobuyoshi Shimizu

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Background: Expression of epidermal growth factor receptor (EGFR) by human breast cancer tissues is associated with poor clinical response. The EGFR tyrosine kinase inhibitor (EGFR-TKI), gefitinib ('Iressa', ZD1839), is a leading example of a molecular targeted agent, and has an anti-proliferative effect on various cancer cells. But the details of the anti-cancer effect and mechanism have not been elucidated. We studied the anti-cancer effect of gefitinib in breast cancer cell lines and the intracellular pathway downstream of EGFR associated with cell migration. Methods: In this study, we analysed the anti-proliferative and anti-migratory effect of gefitinib in EGFR (+) breast cancer cell lines by WST-1 analysis and chemotaxis chamber analysis. We analyzed several intracellular phosphorylated pathways which are activated by mitogen activated kinases (extracellular signal-regulated protein kinase 1 and 2: MEK), phosphatidylinositol 3'-kinase (PI3K) and phpspholipase C (PLC), by blocking those pathways using inhibitors of each kinase, and also investigated the effects on the phosphorylation of myosin light chain (MLC). Results: Gefitinib inhibited proliferation in most of these cell lines. MDA-MB231 was shown to be resistant. Furthermore, proliferation of MDA-MB231 cells was not affected by EGF stimulation, but migration of MDA-MB231 cells was significantly inhibited. PI3K and PLC inhibitors blocked EGF-stimulated cell migration and MLC phosphorylation, but the MEK inhibitor did not influence cell migration. Conclusions: Gefitinib has an anti-migratory effect on MDA-MB231 that results in an anti-proliferative effect. PI3K and PLC are important for the migration of MDA-MB231 cells, and gefitinib may inhibit migration by blocking these signalling pathways.

Original languageEnglish
Pages (from-to)367-373
Number of pages7
JournalBreast Cancer
Volume11
Issue number4
DOIs
Publication statusPublished - Nov 2004

Fingerprint

Phosphatidylinositol 3-Kinase
Epidermal Growth Factor
Cell Movement
Epidermal Growth Factor Receptor
Myosin Light Chains
Mitogen-Activated Protein Kinase Kinases
Breast Neoplasms
Cell Line
Phosphotransferases
Phosphorylation
Neoplasms
Mitogen-Activated Protein Kinase 3
Inhibition (Psychology)
gefitinib
Mitogen-Activated Protein Kinase 1
Chemotaxis
Mitogens
Protein-Tyrosine Kinases
Protein Kinases

Keywords

  • EGFR
  • EGFR-TKI
  • Gefitinib
  • Iressa
  • ZD1839

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Pharmacology (medical)

Cite this

PLC and PI3K pathways are important in the inhibition of EGF-induced cell migration by gefitinib ('Iressa', ZD1839). / Shien, Tadahiko; Doihara, Hiroyoshi; Hara, Humikata; Takahashi, Hirotoshi; Yoshitomi, Seiji; Taira, Naruto; Ishibe, Youiti; Teramoto, Jyun; Aoe, Motoi; Shimizu, Nobuyoshi.

In: Breast Cancer, Vol. 11, No. 4, 11.2004, p. 367-373.

Research output: Contribution to journalArticle

Shien, Tadahiko ; Doihara, Hiroyoshi ; Hara, Humikata ; Takahashi, Hirotoshi ; Yoshitomi, Seiji ; Taira, Naruto ; Ishibe, Youiti ; Teramoto, Jyun ; Aoe, Motoi ; Shimizu, Nobuyoshi. / PLC and PI3K pathways are important in the inhibition of EGF-induced cell migration by gefitinib ('Iressa', ZD1839). In: Breast Cancer. 2004 ; Vol. 11, No. 4. pp. 367-373.
@article{7be98ffd9d824606a8676e075f5b2dc2,
title = "PLC and PI3K pathways are important in the inhibition of EGF-induced cell migration by gefitinib ('Iressa', ZD1839)",
abstract = "Background: Expression of epidermal growth factor receptor (EGFR) by human breast cancer tissues is associated with poor clinical response. The EGFR tyrosine kinase inhibitor (EGFR-TKI), gefitinib ('Iressa', ZD1839), is a leading example of a molecular targeted agent, and has an anti-proliferative effect on various cancer cells. But the details of the anti-cancer effect and mechanism have not been elucidated. We studied the anti-cancer effect of gefitinib in breast cancer cell lines and the intracellular pathway downstream of EGFR associated with cell migration. Methods: In this study, we analysed the anti-proliferative and anti-migratory effect of gefitinib in EGFR (+) breast cancer cell lines by WST-1 analysis and chemotaxis chamber analysis. We analyzed several intracellular phosphorylated pathways which are activated by mitogen activated kinases (extracellular signal-regulated protein kinase 1 and 2: MEK), phosphatidylinositol 3'-kinase (PI3K) and phpspholipase C (PLC), by blocking those pathways using inhibitors of each kinase, and also investigated the effects on the phosphorylation of myosin light chain (MLC). Results: Gefitinib inhibited proliferation in most of these cell lines. MDA-MB231 was shown to be resistant. Furthermore, proliferation of MDA-MB231 cells was not affected by EGF stimulation, but migration of MDA-MB231 cells was significantly inhibited. PI3K and PLC inhibitors blocked EGF-stimulated cell migration and MLC phosphorylation, but the MEK inhibitor did not influence cell migration. Conclusions: Gefitinib has an anti-migratory effect on MDA-MB231 that results in an anti-proliferative effect. PI3K and PLC are important for the migration of MDA-MB231 cells, and gefitinib may inhibit migration by blocking these signalling pathways.",
keywords = "EGFR, EGFR-TKI, Gefitinib, Iressa, ZD1839",
author = "Tadahiko Shien and Hiroyoshi Doihara and Humikata Hara and Hirotoshi Takahashi and Seiji Yoshitomi and Naruto Taira and Youiti Ishibe and Jyun Teramoto and Motoi Aoe and Nobuyoshi Shimizu",
year = "2004",
month = "11",
doi = "10.1007/BF02968044",
language = "English",
volume = "11",
pages = "367--373",
journal = "Breast Cancer",
issn = "1340-6868",
publisher = "Springer Japan",
number = "4",

}

TY - JOUR

T1 - PLC and PI3K pathways are important in the inhibition of EGF-induced cell migration by gefitinib ('Iressa', ZD1839)

AU - Shien, Tadahiko

AU - Doihara, Hiroyoshi

AU - Hara, Humikata

AU - Takahashi, Hirotoshi

AU - Yoshitomi, Seiji

AU - Taira, Naruto

AU - Ishibe, Youiti

AU - Teramoto, Jyun

AU - Aoe, Motoi

AU - Shimizu, Nobuyoshi

PY - 2004/11

Y1 - 2004/11

N2 - Background: Expression of epidermal growth factor receptor (EGFR) by human breast cancer tissues is associated with poor clinical response. The EGFR tyrosine kinase inhibitor (EGFR-TKI), gefitinib ('Iressa', ZD1839), is a leading example of a molecular targeted agent, and has an anti-proliferative effect on various cancer cells. But the details of the anti-cancer effect and mechanism have not been elucidated. We studied the anti-cancer effect of gefitinib in breast cancer cell lines and the intracellular pathway downstream of EGFR associated with cell migration. Methods: In this study, we analysed the anti-proliferative and anti-migratory effect of gefitinib in EGFR (+) breast cancer cell lines by WST-1 analysis and chemotaxis chamber analysis. We analyzed several intracellular phosphorylated pathways which are activated by mitogen activated kinases (extracellular signal-regulated protein kinase 1 and 2: MEK), phosphatidylinositol 3'-kinase (PI3K) and phpspholipase C (PLC), by blocking those pathways using inhibitors of each kinase, and also investigated the effects on the phosphorylation of myosin light chain (MLC). Results: Gefitinib inhibited proliferation in most of these cell lines. MDA-MB231 was shown to be resistant. Furthermore, proliferation of MDA-MB231 cells was not affected by EGF stimulation, but migration of MDA-MB231 cells was significantly inhibited. PI3K and PLC inhibitors blocked EGF-stimulated cell migration and MLC phosphorylation, but the MEK inhibitor did not influence cell migration. Conclusions: Gefitinib has an anti-migratory effect on MDA-MB231 that results in an anti-proliferative effect. PI3K and PLC are important for the migration of MDA-MB231 cells, and gefitinib may inhibit migration by blocking these signalling pathways.

AB - Background: Expression of epidermal growth factor receptor (EGFR) by human breast cancer tissues is associated with poor clinical response. The EGFR tyrosine kinase inhibitor (EGFR-TKI), gefitinib ('Iressa', ZD1839), is a leading example of a molecular targeted agent, and has an anti-proliferative effect on various cancer cells. But the details of the anti-cancer effect and mechanism have not been elucidated. We studied the anti-cancer effect of gefitinib in breast cancer cell lines and the intracellular pathway downstream of EGFR associated with cell migration. Methods: In this study, we analysed the anti-proliferative and anti-migratory effect of gefitinib in EGFR (+) breast cancer cell lines by WST-1 analysis and chemotaxis chamber analysis. We analyzed several intracellular phosphorylated pathways which are activated by mitogen activated kinases (extracellular signal-regulated protein kinase 1 and 2: MEK), phosphatidylinositol 3'-kinase (PI3K) and phpspholipase C (PLC), by blocking those pathways using inhibitors of each kinase, and also investigated the effects on the phosphorylation of myosin light chain (MLC). Results: Gefitinib inhibited proliferation in most of these cell lines. MDA-MB231 was shown to be resistant. Furthermore, proliferation of MDA-MB231 cells was not affected by EGF stimulation, but migration of MDA-MB231 cells was significantly inhibited. PI3K and PLC inhibitors blocked EGF-stimulated cell migration and MLC phosphorylation, but the MEK inhibitor did not influence cell migration. Conclusions: Gefitinib has an anti-migratory effect on MDA-MB231 that results in an anti-proliferative effect. PI3K and PLC are important for the migration of MDA-MB231 cells, and gefitinib may inhibit migration by blocking these signalling pathways.

KW - EGFR

KW - EGFR-TKI

KW - Gefitinib

KW - Iressa

KW - ZD1839

UR - http://www.scopus.com/inward/record.url?scp=18844371753&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18844371753&partnerID=8YFLogxK

U2 - 10.1007/BF02968044

DO - 10.1007/BF02968044

M3 - Article

VL - 11

SP - 367

EP - 373

JO - Breast Cancer

JF - Breast Cancer

SN - 1340-6868

IS - 4

ER -